Autopsy report · NCT05831995

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

“Due to development strategy change.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

ABM Therapeutics Corporation

Sponsor type

Industry

Conditions

Advanced Solid Tumor; RAS Mutation; RAF Mutation; NF1 Mutation

Interventions

ABM-168

Participants

12

Sites

6

Countries

United States

Trials that died the same way

• Study of NIB101 in Participants With Advanced Solid Tumors
  “due to the reconsideration of development strategy” (82% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (82% match in meaning)
• Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
  “Due to corporate strategic adjustment.” (73% match in meaning)
• Improving End-of-life Care by Continuing Medical Education and Electronic Decision Making Support for General Practitioners
  “due to organisational changes” (72% match in meaning)
• Safety and Efficacy of Periodontal Surgery in Supra-alveolar-type Defects With or Without Straumann® Emdogain
  “Due to change in strategy and decision not to expand indication.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.